Head and Neck Squamous Cell Carcinoma Clinical Trials

65 studies are recruiting for head and neck squamous cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

2. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology, Beverly Hills, California

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

3. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

   This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chem…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Anchorage Associates in Radiation Medicine, Anchorage, Alaska

   Locations

   679 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT02734537 on ClinicalTrials.gov

4. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

   A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 105 - START Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   EpiBiologics

   See if you can join NCT07462377 on ClinicalTrials.gov

5. Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

   This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06980038 on ClinicalTrials.gov

6. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

7. A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

   The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   32 in total

   Run by

   Tempus AI

   See if you can join NCT06163534 on ClinicalTrials.gov

8. A Study of IDP-001 in Advanced or Metastatic Solid Tumors

   This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   InduPro, Inc.

   See if you can join NCT07602842 on ClinicalTrials.gov

9. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

   This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, La Jolla, California

   Locations

   5 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07216105 on ClinicalTrials.gov

10. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Gilbert, Arizona

    Locations

    23 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

11. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START-San Antonio, San Antonio, Texas

    Locations

    54 in total

    Run by

    AbbVie

    See if you can join NCT06084481 on ClinicalTrials.gov

12. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Grand Rapids, Michigan

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov

13. PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

    The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06239220 on ClinicalTrials.gov

14. Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

    This phase II trial compares the effect of adding olanzapine to standard of care symptom management for nausea to standard of care alone in managing an abnormal loss of the appetite for food (anorexia) in patients treated with chemoradiation therapy (CRT) for head and neck cancer. Patients undergoi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Roswell Park Cancer Institute, Buffalo, New York

    Run by

    Roswell Park Cancer Institute

    See if you can join NCT06995508 on ClinicalTrials.gov

15. Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

    This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona

    Locations

    153 in total

    Run by

    NRG Oncology

    See if you can join NCT06532279 on ClinicalTrials.gov

16. Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

    This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal antibodies. It binds …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Tower Cancer Research Foundation, Beverly Hills, California

    Locations

    63 in total

    Run by

    NRG Oncology

    See if you can join NCT07441681 on ClinicalTrials.gov

17. A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

    The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    6 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05544136 on ClinicalTrials.gov

18. A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

    Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05859074 on ClinicalTrials.gov

19. 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

    To learn if it is effective to use advanced radiation treatment techniques (stereotactic radiation or "SBRT") to safely deliver a strong dose of radiation to your tumor in a shorter period of time than would typically be feasible with traditional methods.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05674396 on ClinicalTrials.gov

20. CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

    This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A*0201-positive treatment naive participants with locally advanced HPV-16 associated head…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Yale University, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT07172256 on ClinicalTrials.gov

21. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSD, La Jolla, California

    Locations

    54 in total

    Run by

    Merus B.V.

    See if you can join NCT03526835 on ClinicalTrials.gov

22. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists - Lake Nona, Orlando, Florida

    Locations

    10 in total

    Run by

    Compass Therapeutics

    See if you can join NCT06150664 on ClinicalTrials.gov

23. A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

    The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allo…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04722523 on ClinicalTrials.gov

24. Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

    This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemot…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT04375384 on ClinicalTrials.gov

25. Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

    This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation. Cisplatin, a chemotherapy often used to …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Emory Midtown University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT06662058 on ClinicalTrials.gov